GSK plc (GSK)
NYSE: GSK · Real-Time Price · USD
41.15
+0.35 (0.86%)
Jun 5, 2025, 4:00 PM - Market closed

Company Description

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally.

It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer.

It also provides vaccines for Shingles, Meningitis, RSV, Seasonal Influenza, Hepatitis, Diphtheria, Tetanus, Acellular Pertussis, Rotavirus, Pertussis, Polio, Haemophilus, Invasive Diseases, Pneumonia, Acute Otitis Media, Measles, Mumps, Rubella and Chickenpox, and Human Papilloma Virus.

Additionally, the company offers general medicines for asthma, COPD, bacterial infection, benign prostatic hyperplasia, allergic rhinitis, and inflammatory skin conditions.

It has a collaboration agreement with CureVac to develop mRNA vaccines for infectious diseases. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022.

GSK plc was founded in 1715 and is headquartered in London, United Kingdom.

GSK plc
GSK plc logo
Country United Kingdom
Founded 1715
Industry Drug Manufacturers - General
Sector Healthcare
Employees 68,629
CEO Emma Walmsley

Contact Details

Address:
79 New Oxford Street
London, WC1A 1DG
United Kingdom
Phone 44 20 8047 5000
Website gsk.com

Stock Details

Ticker Symbol GSK
Exchange NYSE
Fiscal Year January - December
Reporting Currency GBP
CIK Code 0001131399
CUSIP Number 37733W204
ISIN Number US37733W2044
SIC Code 2834

Key Executives

Name Position
Sally Jackson Senior Vice President of Global Communications and Chief Executive Officer Office
Emma Natasha Walmsley Chief Executive Officer and Director
Julie Belita Brown A.C.A. Chief Financial Officer and Executive Director
Dr. Jesse L. Goodman M.D., M.P.H. Scientific and Medical Expert
Shobie Ramakrishnan Chief Digital and Technology Officer
Tony Wood Chief Scientific Officer and Head of Research & Development
James Ford Senior Vice President and Group General Counsel of Legal & Compliance
David Simon Redfern BSc (Hons), CA President of Corporate Development
Diana Conrad Chief People Officer
Philip C. Thomson President of Global Affairs

Latest SEC Filings

Date Type Title
Jun 5, 2025 6-K Report of foreign issuer
Jun 4, 2025 6-K Report of foreign issuer
Jun 4, 2025 6-K Report of foreign issuer
Jun 3, 2025 6-K Report of foreign issuer
Jun 2, 2025 6-K Report of foreign issuer
Jun 2, 2025 6-K Report of foreign issuer
Jun 2, 2025 6-K Report of foreign issuer
Jun 2, 2025 6-K Report of foreign issuer
May 30, 2025 SD Form - SD
May 30, 2025 6-K Report of foreign issuer